Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL XR 10 vs BAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Arsenic poisoning,Mercury poisoning,Lead poisoning (adjunct to edetate calcium disodium),Acute gold poisoning,Wilson's disease (investigational)
10 mg orally once daily in the morning; maximum dose 40 mg/day.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
Dexamphetamine: 10-13 hours in adults (children: 6-8 hours); levoamphetamine: 13-16 hours; clinically, steady-state achieved in approximately 3 days, with twice-daily dosing maintaining therapeutic levels
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Amphetamine is primarily metabolized by hepatic CYP2D6 to 4-hydroxyamphetamine, which is further conjugated. Minor pathways include N-dealkylation and deamination. The drug has a half-life of approximately 10-13 hours.
Primarily hepatic; undergoes oxidation and conjugation; metabolites excreted renally.
Renal (approximately 30-40% as unchanged amphetamine, remainder as metabolites, including deaminated and oxidized products; urinary p H-dependent elimination: acidic p H increases renal clearance, alkaline p H decreases renal clearance; negligible biliary/fecal elimination)
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
15-40% bound to plasma proteins, primarily albumin; lower binding in patients with hepatic impairment
BAL is extensively bound to plasma proteins, primarily albumin, with protein binding >90%.
3.0-4.5 L/kg for total amphetamine; high tissue distribution (brain, lungs, kidneys); enters CNS via passive diffusion and active transport
Volume of distribution is approximately 3.5 L/kg, indicating extensive distribution into tissues, including brain and intracellular spaces.
Oral: quantitative absorption with 90-100% bioavailability of the total amphetamine content; food does not affect overall absorption but may delay peak concentrations with high-fat meals
BAL is not administered orally due to poor absorption and gastrointestinal irritation. Given intravenously, bioavailability is 100%. Intramuscular bioavailability is similar but with slower absorption.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: not recommended.
GFR 10-50 m L/min: reduce frequency to every 6-8 hours; GFR <10 m L/min: reduce frequency to every 8-12 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor for hepatotoxicity.
Children 6-17 years: starting dose 5 mg once daily; increase by 5 mg weekly based on response; maximum 30 mg/day.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days; maximum 100 mg per dose.
Starting dose 5 mg once daily; increase cautiously with monitoring for hypertension, agitation, and cognitive effects.
Start at 3 mg/kg IM every 6 hours; adjust based on renal function, monitor for hypotension and pain at injection site.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
None.
Serious cardiovascular events, including sudden death in patients with pre-existing structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions (e.g., exacerbation of psychosis, mania, aggression); seizures; serotonin syndrome if combined with serotonergic drugs; long-term growth suppression in children; peripheral vasculopathy including Raynaud's phenomenon; potential for abuse and dependence.
Monitor renal function and serum electrolytes during therapy.,Can cause hypertension, tachycardia, and myocardial ischemia; use cautiously in cardiovascular disease.,May induce hemolytic anemia in patients with G6PD deficiency.,Injection site reactions and sterile abscesses may occur.,Iron deficiency is a known adverse effect due to iron chelation.
Hypersensitivity to amphetamine or any component of the formulation; patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma; agitated states; history of drug abuse; during or within 14 days following MAOI therapy.
Hypersensitivity to BAL or any component.,Hepatic insufficiency (unless benefit outweighs risk).,Iron poisoning (forms toxic complex).,Concurrent use with cadmium or selenium (increased toxicity).
Take ADDERALL XR with or without food. However, high-fat meals may delay absorption and reduce peak concentrations. Avoid consumption of acidic foods or beverages (e.g., citrus fruits, fruit juices, cola) within 1 hour before or after dosing, as acidity can decrease absorption. Vitamin C (ascorbic acid) and other acidifying agents can reduce efficacy; conversely, alkalizing agents (e.g., antacids, sodium bicarbonate) may potentiate effects.
Avoid alcohol and caffeine. Maintain adequate hydration. No specific food restrictions, but ensure iron-rich foods are avoided if concurrent iron poisoning suspected (though BAL not indicated for iron).
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects at high doses. Second trimester: Potential for reduced fetal growth and premature delivery. Third trimester: Risk of neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia) and preterm birth.
Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.
Contraindicated during breastfeeding. Amphetamine is excreted into human milk; M/P ratio approximately 3.5. Infant exposure estimated at 4-8% of maternal weight-adjusted dose. Reported adverse effects in infants include irritability, poor feeding, and sleep disturbances.
BAL (dimercaprol) is excreted into breast milk; M/P ratio unknown. Limited data; exercise caution and consider temporary cessation of breastfeeding during therapy.
Increased clearance during 2nd and 3rd trimesters (hepatic induction) may require dose escalation. Postpartum, clearance returns to nonpregnant levels, requiring dose reduction to avoid toxicity. Individualize dosing based on clinical response and tolerability.
No specific dose adjustments recommended in pregnancy; monitor for increased volume of distribution and potential need for higher doses if toxicity persists.
ADDERALL XR (mixed amphetamine salts extended-release) 10 mg is a CNS stimulant indicated for ADHD. Initiate at 10 mg once daily in the morning; titrate in 5-10 mg increments weekly. Swallow capsules whole, or sprinkle contents on applesauce for patients unable to swallow. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Abuse potential is high; use with caution in patients with history of substance abuse. Contraindicated in glaucoma, hyperthyroidism, agitated states, MAOI use within 14 days, and structural cardiac abnormalities.
BAL (dimercaprol) is used as a chelating agent for heavy metal poisoning, particularly arsenic, lead, and mercury. Administer deep IM only; avoid IV due to risk of hemolysis. Monitor blood pressure closely as hypertension can occur. Contraindicated in peanut allergy due to peanut oil vehicle. Administer with alkaline urine to protect kidneys.
Take exactly as prescribed once daily in the morning with or without food.,Do not chew or crush the capsule; you may open it and sprinkle the beads on a spoonful of applesauce, then swallow immediately without chewing.,Avoid taking in the afternoon or evening as it may cause difficulty sleeping.,Do not stop abruptly without consulting your doctor; sudden discontinuation may cause withdrawal symptoms.,Report any chest pain, palpitations, shortness of breath, or fainting to your doctor.,This medication has a high potential for abuse; keep in a safe place and do not share with others.,Avoid alcohol and illicit drugs while taking this medication.,Notify your doctor if you have a history of drug dependence, anxiety, bipolar disorder, or seizures.,For patients with ADHD, it may improve focus, attention, and impulse control.,Store at room temperature away from moisture and heat.
This medication is given as an injection into a muscle.,You may experience a metallic taste, headache, or nausea.,Report any signs of allergic reaction such as rash or difficulty breathing.,Avoid alcohol while on this medication.,Do not drive or operate heavy machinery until you know how this drug affects you.
No interactions on record
"Pregabalin, a gabapentinoid, enhances the inhibitory effects of GABA by binding to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Dapiprazole, an α1-adrenoceptor antagonist used for miosis, can have its therapeutic efficacy increased when combined with pregabalin due to additive central nervous system depression. This interaction may result in enhanced sedation, dizziness, and psychomotor impairment, potentially increasing the risk of falls and cognitive dysfunction."
"Pregabalin and pravastatin may exhibit an additive risk of musculoskeletal adverse effects, particularly myopathy and rhabdomyolysis, due to their overlapping effects on muscle cells. Pregabalin can cause dose-related muscle damage, while pravastatin inhibits HMG-CoA reductase, leading to reduced skeletal muscle integrity. This combination may potentiate serum creatine kinase elevations and increase the likelihood of clinical myopathy, especially in patients with predisposing factors such as renal impairment or concomitant use of other myotoxic agents."
"Pregabalin may cause fluid retention and peripheral edema, which can precipitate or exacerbate heart failure, especially in patients with pre-existing cardiac risk factors. Rosiglitazone, a thiazolidinedione, also promotes fluid retention and increases plasma volume via PPAR-γ-mediated renal effects. When combined, the additive fluid-retaining properties of both drugs can synergistically elevate the risk of new-onset or worsening heart failure, particularly in patients with reduced left ventricular function or NYHA Class III/IV status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL XR 10 vs BAL, answered by our medical review team.
ADDERALL XR 10 is a CNS Stimulant that works by Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.. BAL is a Chelating Agent that works by Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL XR 10 and BAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL XR 10 is: 10 mg orally once daily in the morning; maximum dose 40 mg/day.. The standard adult dose of BAL is: 3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL XR 10 and BAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL XR 10 is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects a. BAL is classified as Category C. Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.